Skip to main content
Top
Published in: Abdominal Radiology 4/2013

01-08-2013

Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging

Authors: A. Gatto, A. M. De Gaetano, M. Giuga, M. Ciresa, L. Siciliani, L. Miele, L. Riccardi, F. Pizzolante, G. L. Rapaccini, A. Gasbarrini, F. Giuliante, F. M. Vecchio, M. Pompili, L. Bonomo

Published in: Abdominal Radiology | Issue 4/2013

Login to get access

Abstract

Purpose

We evaluated whether the addition of delayed phase imaging (DPI) gadobenate dimeglumine-enhanced MRI to dynamic postcontrast imaging improves the characterization of small hepatocellular carcinoma (HCC) and the differentiation between HCC, high grade dysplastic nodules (HGDN), and low grade dysplastic nodules (LGDN).

Methods

Twenty-five cirrhotic patients with 30 nodules (16 HCC, 8 HGDNs, and 6 LGDNs; maximum size of 3 cm) were included in this retrospective study. The diagnostic reference standard was histology. All the patients underwent MRI both prior to and following intravenous administration of gadobenate dimeglumine. The lesions were classified as hypointense, isointense, hyperintense on DPI for qualitative assessment. In the quantitative analysis the relative tumor-liver contrast to noise ratio (CNR) of the lesions on DPI was calculated.

Results

All HCCs were hypointense on DPI while only 8 (57.1%) of 14 DNs were hypointense and only 1 of 6 (16.6%) LGDNs was hypointense. There was a statistically significant difference in the hypointensity on DPI between HCCs and DNs (p = 0.003) in the qualitative analysis but not in the CNR values while there was a strong statistically significant difference in the hypointensity on DPI in the qualitative (p = 0.00001) and quantitative analysis (p < 0.05) between LGDNs and the group obtained by unifying HGDNs and HCCs.

Conclusion

DPI is helpful in differentiating HCCs and HGDNs from LGDNs. Demonstration of hypointensity on DPI should raise the suspicion of HGDN or hypovascular HCC in the case of nodules with atypical dynamic pattern.
Literature
1.
go back to reference Amit S, Jorge AM (2008) Screening for hepatocellular carcinoma. Gastroenterol Hepatol (NY) 4(3):201–208 Amit S, Jorge AM (2008) Screening for hepatocellular carcinoma. Gastroenterol Hepatol (NY) 4(3):201–208
2.
go back to reference Hussain SM, Zondervan PE, IJzermans JN, et al. (2002) Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 22:1023–1036PubMed Hussain SM, Zondervan PE, IJzermans JN, et al. (2002) Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 22:1023–1036PubMed
3.
go back to reference Matsui O, Kadoya M, Kameyama T, et al. (1991) Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 178:493–497PubMed Matsui O, Kadoya M, Kameyama T, et al. (1991) Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 178:493–497PubMed
4.
go back to reference Bartolozzi C, Battaglia V, Bozzi E (2011) Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR. Abdom Imaging 36:290–299PubMedCrossRef Bartolozzi C, Battaglia V, Bozzi E (2011) Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR. Abdom Imaging 36:290–299PubMedCrossRef
5.
go back to reference Caudana R, Morana G, Pirovano G, et al. (1996) Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)—preliminary results of phase II clinical application. Radiology 199:513–520PubMed Caudana R, Morana G, Pirovano G, et al. (1996) Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)—preliminary results of phase II clinical application. Radiology 199:513–520PubMed
6.
go back to reference Kim YK, Lee JM, Kim CS (2004) Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 14:5–13PubMedCrossRef Kim YK, Lee JM, Kim CS (2004) Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 14:5–13PubMedCrossRef
7.
go back to reference Pirovano G, Vanzulli A, Marti-Bonmati L, et al. (2000) Evaluation of the Accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. Am J Roentgenol 175:1111–1120CrossRef Pirovano G, Vanzulli A, Marti-Bonmati L, et al. (2000) Evaluation of the Accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. Am J Roentgenol 175:1111–1120CrossRef
8.
go back to reference Manfredi R, Maresca G, Baron RL, et al. (1999) Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 9:704–710PubMedCrossRef Manfredi R, Maresca G, Baron RL, et al. (1999) Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 9:704–710PubMedCrossRef
9.
go back to reference Bruix J, Sherman M (2011) American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022PubMedCrossRef Bruix J, Sherman M (2011) American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022PubMedCrossRef
10.
go back to reference International Working Party (1995) Terminology of nodular hepatocellular lesions. Hepatology 22:983–993 International Working Party (1995) Terminology of nodular hepatocellular lesions. Hepatology 22:983–993
11.
go back to reference International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658–664CrossRef International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658–664CrossRef
12.
14.
go back to reference Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 6:282–291PubMedCrossRef Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 6:282–291PubMedCrossRef
15.
go back to reference Kirchin MA, Pirovano G, Spinazzi A (1998) gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 33:798–809PubMedCrossRef Kirchin MA, Pirovano G, Spinazzi A (1998) gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 33:798–809PubMedCrossRef
16.
go back to reference Cavagna FM, Maggioni F, Castelli PM, et al. (1997) Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780–796PubMedCrossRef Cavagna FM, Maggioni F, Castelli PM, et al. (1997) Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780–796PubMedCrossRef
17.
go back to reference Pena CS, Saini S, Baron RL, et al. (2001) Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial. Korean J Radiol 2(4):210–215PubMedCrossRef Pena CS, Saini S, Baron RL, et al. (2001) Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial. Korean J Radiol 2(4):210–215PubMedCrossRef
18.
go back to reference Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43(3):202–210PubMedCrossRef Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43(3):202–210PubMedCrossRef
19.
go back to reference Bartolozzi C, Battaglia V, Bozzi E (2009) HCC diagnosis with liver-specific MRI-close to histopathology. Dig Dis 27:125–130PubMedCrossRef Bartolozzi C, Battaglia V, Bozzi E (2009) HCC diagnosis with liver-specific MRI-close to histopathology. Dig Dis 27:125–130PubMedCrossRef
20.
go back to reference Kim TK, Lee KH, Jang HJ, et al. (2011) Analysis of gadobenate dimeglumine-enhanced MR Findings for characterizing small (1–2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 259(3):730–738PubMedCrossRef Kim TK, Lee KH, Jang HJ, et al. (2011) Analysis of gadobenate dimeglumine-enhanced MR Findings for characterizing small (1–2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 259(3):730–738PubMedCrossRef
21.
go back to reference Morana G, Grazioli L, Kirchin MA, et al. (2011) Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 46(4):225–239PubMedCrossRef Morana G, Grazioli L, Kirchin MA, et al. (2011) Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 46(4):225–239PubMedCrossRef
22.
go back to reference Tahir B, Sandrasegaran K, Ramaswamy R, et al. (2011) Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade? Clin Radiol 66(9):845–852PubMedCrossRef Tahir B, Sandrasegaran K, Ramaswamy R, et al. (2011) Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade? Clin Radiol 66(9):845–852PubMedCrossRef
23.
go back to reference Matsui O (2004) Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology 47(3–5):271–276PubMedCrossRef Matsui O (2004) Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology 47(3–5):271–276PubMedCrossRef
24.
go back to reference Matsui O, Kobayashi S, Sanada J, et al. (2011) Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 36(3):264–272PubMedCrossRef Matsui O, Kobayashi S, Sanada J, et al. (2011) Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 36(3):264–272PubMedCrossRef
25.
go back to reference Willatt JM, Hussain HK, Adusumilli S, Marrero JA (2008) MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 247(2):311–329PubMedCrossRef Willatt JM, Hussain HK, Adusumilli S, Marrero JA (2008) MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 247(2):311–329PubMedCrossRef
26.
go back to reference Theise ND, Park YN, Kojiro M, et al. (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6(2):497–512PubMedCrossRef Theise ND, Park YN, Kojiro M, et al. (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6(2):497–512PubMedCrossRef
27.
go back to reference Kobayashi M, Ikeda K, Hosaka T, et al. (2006) Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 106(3):636–647PubMedCrossRef Kobayashi M, Ikeda K, Hosaka T, et al. (2006) Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 106(3):636–647PubMedCrossRef
28.
go back to reference Borzio M, Fargion S, Borzio F, et al. (2003) Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 39(2):208–214PubMedCrossRef Borzio M, Fargion S, Borzio F, et al. (2003) Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 39(2):208–214PubMedCrossRef
Metadata
Title
Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging
Authors
A. Gatto
A. M. De Gaetano
M. Giuga
M. Ciresa
L. Siciliani
L. Miele
L. Riccardi
F. Pizzolante
G. L. Rapaccini
A. Gasbarrini
F. Giuliante
F. M. Vecchio
M. Pompili
L. Bonomo
Publication date
01-08-2013
Publisher
Springer US
Published in
Abdominal Radiology / Issue 4/2013
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-012-9950-y

Other articles of this Issue 4/2013

Abdominal Radiology 4/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.